Dexmedetomidine in Topical Versus Peribulbar Anesthesia for Cataract Surgery
Launched by KAFRELSHEIKH UNIVERSITY · Jan 11, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called dexmedetomidine to see how well it works when added to two different types of anesthesia during cataract surgery. One type is called topical anesthesia, which is applied directly to the eye, and the other is peribulbar anesthesia, which involves an injection near the eye. The goal is to find out which method helps patients feel more comfortable during the surgery.
To participate in this trial, you need to be between 76 and 74 years old and have a physical health status classified as I or II, meaning you are generally healthy or have mild health issues. Unfortunately, people under 18, those with certain health conditions like severe heart disease or lung problems, and anyone with allergies to the study medications cannot join. If you decide to participate, you can expect to receive either type of anesthesia along with dexmedetomidine and will be monitored closely to see how well the anesthesia works during your surgery. This study is currently looking for participants, and everyone is welcome, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) physical status classification I or II who scheduled for eye surgery
- Exclusion Criteria:
- • Patients who are younger than 18 years
- • The usual contraindications for regional anesthesia such as patients refusing LA
- • Clotting abnormalities
- • Impaired mental status
- • Allergy to any of the study medications
- • patients had the severe cardiac disease
- • chronic obstructive lung disease and a history of sleep apnea
- • contraindications to the use of dexmedetomidine
- • history or significant cardiovascular disease risk factors
- • significant coronary artery disease or any known genetic predisposition
- • history of any kind of drug allergy
- • drug abuse
- • psychological or other emotional problems
- • special diet or lifestyle
- • clinically significant abnormal findings in physical examination
- • electrocardiographic (ECG) or laboratory screening
- • known systemic disease requiring the use of anticoagulants.
About Kafrelsheikh University
Kafrelsheikh University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that contribute to the enhancement of healthcare practices and patient outcomes. With a strong emphasis on interdisciplinary collaboration, the university harnesses its diverse expertise in medical sciences, engineering, and technology to conduct rigorous clinical studies. Kafrelsheikh University aims to foster innovation in clinical research, ensuring compliance with ethical standards and regulatory requirements, while actively engaging in community health initiatives to address pressing health challenges. Through its commitment to excellence, the university seeks to develop evidence-based solutions that improve health and well-being at both local and global levels.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kafrelsheikh, , Egypt
Kafr Ash Shaykh, Kafrelsheikh, Egypt
Patients applied
Trial Officials
Mohammed F Algyar, MD
Principal Investigator
Lecturer of Anaesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Kafrelsheikh University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials